XML 40 R15.htm IDEA: XBRL DOCUMENT v3.22.2

Revenue (Tables)

6 Months Ended

Jun. 30, 2022

Revenue

Schedule of revenue by type and collaboration partner under agreements

​

​	​	​	​	​
​		6 Months Ended		6 Months Ended
​	​	June 30, 2022	​	June 30, 2021
(DKK million)	​	​	​	​
Revenue by type:		​
Royalties		4,727		2,595
Reimbursement revenue		287		227
Milestone revenue		176		731
Collaboration revenue	​	91	​	—
Total		5,281		3,553
​	​	​	​	​
Revenue by collaboration partner:		​		​
Janssen		4,206		2,846
AbbVie		—		245
Roche	​	390	​	162
Novartis	​	305	​	73
BioNTech	​	231	​	171
Seagen	​	138	​	56
Other	​	11	​	—
Total		5,281		3,553
​	​	​	​	​
Royalties by product:	​	​	​	​
DARZALEX		4,024		2,360
TEPEZZA		390		162
Kesimpta	​	296	​	72
Other	​	17	​	1
Total		4,727		2,595
​	​	​	​	​

X

- Definition

The disclosure of the disaggregation of revenue from contracts with customers. [Refer: Revenue from contracts with customers]

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Name IFRS
-Number 15
-IssueDate 2021-01-01
-Paragraph 114
-URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=15&code=ifrs-tx-2021-en-r&anchor=para_114&doctype=Standard
-URIDate 2021-03-24

+ Details

Name:	ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersExplanatory
Namespace Prefix:	ifrs-full_
Data Type:	nonnum:textBlockItemType
Balance Type:	na
Period Type:	duration

X

- References

No definition available.

+ Details

Name:	ifrs-full_RevenueAbstract
Namespace Prefix:	ifrs-full_
Data Type:	xbrli:stringItemType
Balance Type:	na
Period Type:	duration